Seattle Genetics and Bristol-Myers Squibb

[1] Seattle Genetics and Bristol-Myers Squibb Evaluate Combination of Brentuximab Vedotin and Nivolumab – ADC Review | Journal of Antibody-drug Conjugates [Article]